Citation Impact
Citing Papers
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
2015
Suppression of Aging in Mice by the Hormone Klotho
2005 StandoutScience
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
2004 Science
The EGF/CSF-1 Paracrine Invasion Loop Can Be Triggered by Heregulin β1 and CXCL12
2009
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
2004
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Nuclear Lamin-A Scales with Tissue Stiffness and Enhances Matrix-Directed Differentiation
2013 StandoutScience
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
2014 Standout
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
2008
Hierarchical Mechanisms for Direct Reprogramming of Fibroblasts to Neurons
2013 StandoutNobel
Modulation of Epidermal Growth Factor Receptor in Endocrine‐Resistant, Estrogen‐Receptor‐Positive Breast Cancer
2002
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.
2001
Cloning, Chromosomal Localization, and Functional Analysis of the Murine Estrogen Receptor β
1997
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
The insulin-like growth factor system and cancer
2003
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene
2003 StandoutNobel
Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells
2007
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
2003
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Different Residues of the Human Estrogen Receptor Are Involved in the Recognition of Structurally Diverse Estrogens and Antiestrogens
1997
Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistance
2010
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
Catalytic Enantioselective 1,6‐Conjugate Addition of Grignard Reagents to Linear Dienoates
2007 StandoutNobel
Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets
2003
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
2005
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Differential Response of Estrogen Receptor α and Estrogen Receptor β to Partial Estrogen Agonists/Antagonists
1998
Historical perspective on hormonal therapy of advanced breast cancer
2002
Antiestrogens upregulate estrogen receptor β expression and inhibit adrenocortical H295R cell proliferation
2005
Fulvestrant (ICI 182,780)-dependent Interacting Proteins Mediate Immobilization and Degradation of Estrogen Receptor-α
2006
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Pioneer transcription factors: establishing competence for gene expression
2011
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis
2009
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer
2003
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
2005 Standout
PTEN Deletion and Concomitant c-Myc Activation Do Not Lead to Tumor Formation in Pancreatic β Cells
2008 StandoutNobel
Targeting multiple signal transduction pathways through inhibition of Hsp90
2004
Molecular basis of agonism and antagonism in the oestrogen receptor
1997 StandoutNature
Catalytic Asymmetric Torgov Cyclization: A Concise Total Synthesis of (+)‐Estrone
2014 StandoutNobel
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
2004
Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy
1996
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Metastatic colonization by circulating tumour cells
2016 StandoutNature
The Mechanism of ICI 164,384 Antiestrogenieity Involves Rapid Loss of Estrogen Receptor in Uterine Tissue
1991
Biological determinants of endocrine resistance in breast cancer
2009
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005
Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective
2004
Structural Insights into the Mode of Action of a Pure Antiestrogen
2001
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
FOXA1 is a key determinant of estrogen receptor function and endocrine response
2010
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
2007
Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)*
2001
Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene.
1993 StandoutNobel
Trends in Kinase Selectivity: Insights for Target Class-Focused Library Screening
2010
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
2004
Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments
2000
Fulvestrant (Faslodex®)—How to Make a Good Drug Better
2007
A potent specific pure antiestrogen with clinical potential.
1991 Standout
Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer
2007
The NEDD8 Pathway Is Required for Proteasome-Mediated Degradation of Human Estrogen Receptor (ER)-α and Essential for the Antiproliferative Activity of ICI 182,780 in ERα-Positive Breast Cancer Cells
2003
Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells.
2003
Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens.
1995
Copper-mediated 1,6-, 1,8-, 1,10- and 1,12-addition and 1,5-substitution reactions in organic synthesis
1999
Generation and reproductive phenotypes of mice lacking estrogen receptor β
1998 StandoutNobel
Binding of (3H)prostaglandin E1 to putative receptors linked to adenylate cyclase of cultured cell clones.
1976 StandoutNobel
Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1
2011 StandoutNobel
Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells.
2003
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
2005
The quinone reductase gene: A unique estrogen receptor-regulated gene that is activated by antiestrogens
1997
Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway
2009
Estradiol attenuates directed migration of vascular smooth muscle cells in vitro.
1996
Characterization of Prostaglandin Receptors in the Bovine Corpus Luteum Cell Membranes
1974
Cancer Genome Landscapes
2013 StandoutScience
Differential Oestrogen Receptor Binding is Associated with Clinical Outcome in Breast Cancer
2012
Occurrence and Properties of a Prostaglandin F2α Receptor in Bovine Corpora Lutea
1975 StandoutNobel
Regulation of prostaglandin receptors by prostaglandins and guanine nucleotides in frog erythrocytes.
1977 StandoutNobel
Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites
1997 StandoutScience
The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site
1997
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer
2005
Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase
1995 StandoutScience
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Autophagy as a Regulated Pathway of Cellular Degradation
2000 StandoutScience
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
2013 Standout
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
2006 StandoutScience
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
Correlation of prostaglandin E1 receptor binding with evoked uterine contraction: Modification by disulfide reduction
1974
Estrogen inhibits the vascular injury response in estrogen receptor β-deficient female mice
1999 StandoutNobel
Works of Alan E. Wakeling being referenced
Oestrogen Receptor-Mediated Modulation of the EGFR/MAPK Pathway in Tamoxifen-Resistant MCF-7 Cells
2003
Use of pure antioestrogens to elucidate the mode of action of oestrogens
1995
The future of new pure antiestrogens in clinical breast cancer
1993
Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes
1996
Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells
2003
MCF‐7 human mammary adenocarcinoma cell death in vitro in response to hormone‐withdrawal and dna damage
1995
Interaction of the antioestrogen ICI 164,384 with the oestrogen receptor
1988
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839)
2004
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
1994
ICI 182,780 (Faslodex?)
2000
Novel steroidal pure antiestrogens
1989
Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells
2004
Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor
2002
Regulation of progesterone receptor mRNA by oestradiol and antioestrogens in breast cancer cell lines
1989
ICI 182,780, a new antioestrogen with clinical potential
1992
Prostaglandin receptors in the hamster uterus during the estrous cycle
1973
BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
2025
New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145
1997
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
1994
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.
1993
Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition.
2004
In vitro studies on the nature of prostaglandin E1 binding in the hamster uterus
1974